This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

SQNM, NVS And ALXN, 3 Health Care Stocks Pushing The Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average (^DJI) trading up 3 points (0.0%) at 15,545 as of Thursday, July 25, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,346 issues advancing vs. 1,602 declining with 83 unchanged.

The Health Care sector currently sits up 0.5% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include Humana (HUM), down 2.3%, Intuitive Surgical (ISRG), down 2.5%, WellPoint (WLP), down 1.7%, Bristol-Myers Squibb Company (BMY), down 1.1% and Baxter International (BAX), down 1.1%. Top gainers within the sector include Boston Scientific (BSX), up 11.6%, Vertex Pharmaceuticals (VRTX), up 2.5%, Amgen (AMGN), up 1.9%, Celgene Corporation (CELG), up 1.7% and Biogen Idec (BIIB), up 1.4%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Sequenom (SQNM) is one of the companies pushing the Health Care sector lower today. As of noon trading, Sequenom is down $1.41 (-30.1%) to $3.28 on heavy volume. Thus far, 27.5 million shares of Sequenom exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $3.00-$3.42 after having opened the day at $3.07 as compared to the previous trading day's close of $4.69.

Sequenom, Inc., a life sciences company, provides genetic analysis solutions in the United States and internationally. It operates through two segments, Molecular Diagnostics and Genetic Analysis. Sequenom has a market cap of $519.3 million and is part of the drugs industry. Shares are down 4.2% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Sequenom a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Sequenom as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally high debt management risk and feeble growth in its earnings per share. Get the full Sequenom Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 17,113.54 +61.81 0.36%
S&P 500 1,983.53 +9.90 0.50%
NASDAQ 4,456.0160 +31.3120 0.71%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs